Evidence map›Paper›PMID 39868332›Full record

ArticlebioRxiv : the preprint server for biology2025

Invasive lobular carcinoma integrated multi-omics analysis reveals silencing of Arginosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance.

Annapurna Gupta, Fouad Choueiry, Jesse Reardon, Nikhil Pramod, Anagh Kulkarni, Eswar Shankar, Steven T Sizemore, Daniel G Stover, Jiangjiang Zhu, Bhuvaneswari Ramaswamy and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Annapurna GuptaDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Fouad ChoueiryDepartment of Human Sciences, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Jesse ReardonDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Nikhil PramodDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Anagh KulkarniDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Eswar ShankarDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Steven T SizemoreDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Daniel G StoverDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID 0000-0001-9003-8165
Jiangjiang ZhuDepartment of Human Sciences, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Bhuvaneswari RamaswamyDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Sarmila MajumderDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Funding

Characterizing the Metabolome and Volatilome of Gut MicrobiomeR35GM133510 · NIGMS · OHIO STATE UNIVERSITY · PI ZHU, JIANGJIANG · 2019 to 2023
$2.2M
NIGMS NIH HHS R35 GM133510
6 · The paper itself

Abstract

Invasive Lobular Carcinoma (ILC), a distinct subtype of breast cancer is hallmarked by E-Cadherin loss, slow proliferation, and strong hormone receptor positivity. ILC faces significant challenges in clinical management due to advanced stage at diagnosis, late recurrence, and development of resistance to endocrine therapy - a cornerstone of ILC treatment. To elucidate the mechanisms underlying endocrine resistance in ILC, ILC cell lines (MDA-MB-134-VI, SUM44PE) were generated to be resistant to tamoxifen, a selective estrogen receptor modulator. The tamoxifen-resistant (TAMR) cells exhibit a 2-fold increase tamoxifen IC

Identifiers

PMID39868332
PMCPMC11761122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.